INTRODUCTION 24
Immunization programs in low and middle income countries (LMICs) face numerous challenges in 25 getting life-saving vaccines to the people who need them. After entering a country, vaccine vials 26 typically travel by road through two to four storage locations before arriving at clinics where health 27 workers administer doses to patients. [1] Non-vaccine costs of routine immunization systems are 28 expected to rise by 80% between 2010 and 2020, with more than one-third of these costs attributable 29 to supply chain logistics.
[2] Supply chain bottlenecks and inefficiencies can cause vaccines to spoil and 30 valuable resources to be wasted before vaccines reach the people who need them, suggesting a need 31 for innovative and lower cost methods for distribution. As non-military unmanned aerial vehicle (UAV) 32 technology has advanced in recent years, interest in potential humanitarian and development use cases 33
for UAVs have proliferated due to their ability to traverse difficult terrains, reduce labor, and replace 34 fleets of vehicles. UAVs have already been successfully deployed for surveillance and aid delivery in 35 humanitarian sectors and commercial systems are currently being developed to transport medical 36 samples and supplies, including vaccines.[3-5] 37
Despite this growing interest, limited evidence is available regarding the impact of UAVs for routine 38 delivery of medical supplies. As with any new technology, the costs of purchasing, maintaining, and 39 operating UAVs and their supporting launch/recovery and maintenance infrastructure -collectively 40 called an unmanned aerial system (UAS) -may be prohibitive. The limited carrying capacity and required 41 flight conditions of UAVs may also pose significant obstacles. Determining whether a UAS would be 42 beneficial to an immunization program is difficult without a model to forecast supply chain performance 43 and costs. We used simulation modeling to assess the impact of using a UAS for vaccine distribution 44 under a range of circumstances and to identify the necessary conditions for a UAS to be favorable over 45 traditional land-based transport. 46 47
HERMES Models of Gaza Province, Mozambique Vaccine Supply Chain 48
Our team used our HERMES (Highly Extensible Resource for Modeling Event-driven Supply Chains) 49 software platform, described in previous publications, [6, 7] Table 1 . 57
The traditional multi-tiered land transport system (TMLTS) for distributing vaccines throughout Gaza 58 consists of three tiers (Figure 1a) . One provincial store picks up vaccines from the national warehouse 59 quarterly using a 4x4 truck (taking additional trips as needed, due to limited cold storage and transport 60 capacity) and delivers monthly to 12 district stores. Districts distribute vaccines to 123 health centers 61 each month using a combination of pick-up truck or motorbike deliveries and health workers traveling 62 via public transit to pick up vaccines. Health workers administer vaccines to the population at each 63 health center. 64
One commercial UAS currently under development for the distribution of medical samples and health 65 products utilizes fixed-wing, battery powered vehicles and fixed hubs for vaccine storage and the 66 launching, recovery, storage, and maintenance of UAVs. We modeled a potential implementation of this 67 system in Gaza province (Figure 1b ) in which the provincial store delivers vaccines monthly to three UAS 68 hubs supplying the 106 health centers in southern Gaza via UAV shipments on an as-needed basis to 69 4 meet population demand. Modeling scenarios assumed that each UAV can carry 1.5L of vaccines to a 70 health center as far as 75km from its hub, a range and payload well within currently available UAV 71 specifications (for example, Wings for Aid offers a UAV that can carry up to 100kg with a range of 72 500km) [9, 10] . Because northern Gaza has a much lower population density which would require a 73 relatively large number of hubs to supply a small number of health centers, we included the TMLTS in 74 the northern region where 3 district stores would supply 17 health centers. 75
The above systems provided a baseline comparison between the TMLTS and a realistic UAS 76 implementation -alongside the TMLTS in the north -to serve the entire province of Gaza. To account 77 for other possible current and future UAVs, sensitivity analyses varied baseline characteristics of the UAS 78 as well as the environment, population, and vaccine schedule and aimed to identify necessary 79 conditions for the UAS to be advantageous. For a direct comparison between the TMLTS and a supply 80 chain using the UAS throughout, these experiments studied a subset of the locations in the Gaza vaccine 81 supply chain which included only the provincial store and locations within its 75km radius. 
Logistics cost per dose administered = Annual logistics costs ÷ Annual vaccine doses administered 93
Logistics costs included storage (storage equipment maintenance, energy, and amortization), transport 94 (driver per diems and vehicle maintenance, fuel/electricity, and amortization), buildings (infrastructure 95 overhead and amortization at storage and immunization locations), and labor (personnel wages for time 96 dedicated to supply chain logistics) and are defined in detail in a previous publication. [ 
11] 97
We also calculated the cost savings of the UAS over the TMLTS: 98
UAS cost savings per dose administered = Logistics cost per dose administered UAS -Logistics cost per dose 99

administered TMLTS 100
Sensitivity analyses using the ≤75km subset locations varied the following factors: 101 Additionally, we identified cost savings thresholds (i.e. tipping points at which the UAS ceases to achieve 112 cost savings over the TMLTS) for the following UAS characteristics, both under the 2015 EPI schedule 113 and after vaccine introductions: 114 6  Payload is the maximum volume of vaccines each UAV can carry in a single shipment. While the 115 above analyses used estimates for UAS costs and useful lifetimes for production at scale, we 116 identified the payload threshold under both at-scale and current cost/lifetime estimates, for 117 both vaccine schedules considered. 118  Cost per UAV round trip and annual hub cost include the costs of energy, amortization, and 119 maintenance. We identified cost thresholds under both vaccine schedules with no flight delays, 120 as well as with each flight having a 50% probability of a delay lasting between one and four 121 weeks. 122
RESULTS 123
Baseline Scenario 124
In the baseline scenario, implementing the UAS improved vaccine availability (96% versus 94% for a 2% 125 increase) and reduced costs ($0.33 (2015 USD) versus $0.41 per dose administered for cost savings of 126 $0.08 per dose administered) as compared to the TMLTS. Vaccine availability improved due to the UAS 127 relieving transport bottlenecks in several routes supplying health centers. These bottlenecks arose in the 128 TMLTS where vaccine carriers lacked sufficient capacity to hold a one-month supply for health centers; 129 UAV shipments were able to occur more frequently and were thereby able to distribute the necessary 130 quantities of vaccines. The UAS offered cost savings through lower transport, per diem, and labor costs 131 that offset the additional hub infrastructure costs. 132
Results were heterogeneous across the province, and comparing the TMLTS to the UAS in individual 133 regions revealed that one of the UAS hubs did not produce cost savings over the TMLTS in the area it 134 served, instead raising logistics costs by $0.11 per dose administered. Of the three hubs, this location 135 served the smallest total population, with the lowest average number of patients per health center. The7 TMLTS was therefore able to effectively supply the region via monthly shipments, while the UAS hub 137 was not sufficiently utilized for its lower per-trip costs to offset its higher annual infrastructure costs. 138
≤75km Subset Scenarios 139
These findings were fairly robust to sensitivity analyses. In fact, the benefits of the UAS increased with 140 certain variations on each parameter, with the exception of vaccine introductions. For the ≤75km subset 141 locations, implementing the UAS raised vaccine availability to 100% (versus 97%) and produced cost 142 savings of $0.08 per dose administered ($0.22 versus $0.31) as compared to the TMLTS, and the UAS 143 maintained cost savings in all sensitivity analyses performed (summarized in Figure 2 ). Varying road 144 speed had the greatest impact and only improved the cost savings offered by the UAS. Raising the 145 average road speed from the baseline of 59km/hr to 100km/hr had no effect on cost savings, while 146 reducing road speed to 5km/hr raised the cost savings per dose administered to $0.21. Population 147 throughput produced the second-greatest effect and was able to both raise and decrease the cost 148 savings achieved. A 100% increase in the average birth cohort (from a baseline of 360 newborns 149 annually to 720 newborns) decreased cost savings of the UAS to $0.05 per dose administered, while a 150 50% reduction (to 180 newborns annually) raised cost savings to $0.16. 151
Varying road distance was also able to both raise and decrease UAS cost savings, yielding the third-152 greatest impact. Raising the average one-way distance of all routes from a baseline of 77km to 154km 153 raised cost savings of the UAS to $0.14, and reducing the average distance to 39km decreased cost 154 savings to $0.06 per dose administered. Distributing the existing population evenly across all health 155 centers had no effect on cost savings, while placing 70% of the population at three urban centers raised 156 cost savings of the UAS to $0.12 per dose administered. Seasonality causing 80% of health centers to be 157 unreachable by land transport for four months annually also raised UAS cost savings to $0.12 per dose 158 8 administered. Finally, introducing RV, IPV, HPV, and MSD to the EPI schedule slightly decreased cost 159 savings by <$0.01 per dose administered. 160
Cost Savings Thresholds 161
The minimum UAV payloads necessary to achieve cost savings over the TMLTS, for the various vaccine 162 schedules and UAS costs and lifetimes tested, were substantially smaller than the currently assumed 163 UAV payload of 1.5L. In order to achieve cost savings over the TMLTS, each UAV was required to have a 164 payload of at least 0.15L for the baseline EPI schedule and 0.20L after RV, IPV, HPV, and MSD were 165 introduced, assuming at-scale estimates for UAS costs and useful lifetimes. Using current estimates, the 166 minimum payload to achieve cost savings was 0.20L under the baseline EPI schedule and 0.40L after 167 vaccine introductions. 168
Similarly, the maximum UAS costs that could achieve savings over the TMLTS were greater than the 169 currently assumed costs under realistic flight conditions. UAS modeled requires levels of cellular, radio, and internet coverage which may be a limitation in 218 remote areas. Appropriate packing to maintain vaccine quality still requires testing in operational 219 conditions. 220
Modeling can not only determine whether a particular UAS could be advantageous in a given setting but 221 may also help guide the development of any UAS to ensure that it will be broadly applicable in a wide 222 range of settings. Our findings indicate that vaccine supply chains may benefit from a UAS, under the 223 right conditions. Future modeling work can further help to identify primary cost drivers and 224 circumstances under which a UAS would provide the greatest efficiencies and ultimately assist in 225 developing a target product profile (TPP) to guide UAS development, investment, and implementation. 226
LIMITATIONS 227
By definition, models are simplified representations and cannot incorporate all aspects of a system. The 228 commercial UAS industry targeting the development sector is immature and limited data are available 229 on operational costs at scale in environments like the one modeled. Our baseline scenario used 230 currently publicly available UAS characteristics[4, 9, 10, 12]; however, to account for the range of 231 possible UAS characteristics, we conducted extensive sensitivity analyses and aimed to find the 232 thresholds at which a UAS would become cost saving. Our sensitivity analyses may not cover all possible 233 values of each parameter studied, and it is possible that factors not included in this study may 234 significantly impact UAS performance and costs. As commercial UAS remain under development for 235 commodity and vaccine distribution, our study assumes that the appropriate technologies can be 236 developed within the costs and operating parameters assumed in this study. A UAS may be prevented 237 from functioning in reality as it would in a simulation due to factors including user error, equipment 238 malfunctions or breakdowns, network outages, and unexpected inclement weather conditions. 239
CONCLUSION 240
Implementing a UAS could increase vaccine availability and decrease costs in a wide range of settings 241 and circumstances if the drones are used frequently enough to overcome the capital costs of installing 242 and maintaining the system. Our computational model showed that major drivers of cost savings from 243 using the UAS are road speed of traditional land vehicles, the number of people needing to be 244 vaccinated, and the distance that needs to be traveled. Maximum costs (including energy, amortization, and maintenance) of UAVs and hubs, for UAS to 323 produce cost savings over TMLTS. Each UAV flight has a 50% probability of delay. The UAS was unable to 324 achieve cost savings in the scenario with four-week delays after vaccine introductions. 325 326 
